GNMSF (Genmab AS) Price-to-Tangible-Book : 3.90 (As of Apr. 15, 2025)

View and export this data going back to . Start your Free Trial

What is Genmab AS Price-to-Tangible-Book?

As of today (2025-04-15), Genmab AS's share price is $188.05. Genmab AS's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $48.22. Hence, Genmab AS's Price to Tangible Book Ratio of today is 3.90.

The historical rank and industry rank for Genmab AS's Price-to-Tangible-Book or its related term are showing as below:

GNMSF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.57 Med: 8.23 Max: 16.58
Current: 3.68

During the past 13 years, Genmab AS's highest Price to Tangible Book Ratio was 16.58. The lowest was 3.57. And the median was 8.23.

GNMSF's Price-to-Tangible-Book is ranked worse than
64.53% of 1204 companies
in the Biotechnology industry
Industry Median: 2.44 vs GNMSF: 3.68

A closely related ratio is called PB Ratio. As of today, Genmab AS's share price is $188.05. Genmab AS's Book Value per Sharefor the quarter that ended in Dec. 2024 was $81.09. Hence, Genmab AS's P/B Ratio of today is 2.32.

Genmab AS Price-to-Tangible-Book Historical Data

The historical data trend for Genmab AS's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Price-to-Tangible-Book Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

Get a 7-Day Free Trial

8.91

7.70

7.23

4.47

4.30

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial															4.47	4.22	6.57	5.56	4.30

Competitive Comparison of Genmab AS's Price-to-Tangible-Book

For the Biotechnology subindustry, Genmab AS's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Genmab AS's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Genmab AS Price-to-Tangible-Book Calculation

Genmab AS's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	188.05	/	48.215
	=	3.90

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Genmab AS Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Genmab AS's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.